Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

Mooi instap moment Dendreon

1.743 Posts
Pagina: «« 1 ... 29 30 31 32 33 ... 88 »» | Laatste | Omlaag ↓
  1. aossa 26 maart 2007 23:12

    • aossa

      Lid sinds: 23 mei 2003

      Laatste bezoek: 15 feb 2025

    • Aanbevelingen

      Ontvangen: 4053

      Gegeven: 3339

    •    Aantal posts: 17.622

    Imo de enige winnaars zijn shorters.

    Short Intrest: 26.419.737 +30%

    Now Schwab is calling for my shares!!!!
    At first it was just an e-mail request for Schwab to "borrow" my shares for their clients that are shorting DNDN. Then it was a nice letter, now I just received a phone call at my office from my Schwab rep telling me about this GREAT investment opportunity for me to make some nice coin IF I allow Schwab to borrow my shares. I started laughing, then she started laughing. I flat out told her that I hope the short interest a-holes cannot find one fricking share of DNDN, then she was really laughing. Her comment to me, "That's been the normal reaction from everybody that I've called, good luck with your DNDN investment." I told her, I don't need luck, I've got science and progress on my side!!!

    Dig in, trust your dd and the Lord knows we've been more than patient. Take care and enjoy the day (except the shorts, screw them!!!) I always do!!!!!

    www.investorvillage.com/smbd.asp?mb=9...
  2. [verwijderd] 27 maart 2007 15:10

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dendreon to Hold Post Advisory Committee Conference Call

    SEATTLE, WA, March 27, 2007 - Dendreon Corporation (Nasdaq: DNDN) today announced the Company will hold a conference call on Thursday evening to discuss the outcome of the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee meeting for Provenge(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy under review for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer.

    Time: 7:30 pm ET / 6:30 pm CT / 5:30 pm MT / 4:30 pm PT
    Date: March 29, 2007
    Dial-in: 1-800-289-0572 (domestic) or +1-913-981-5543 (international)
    Webcast: www.dendreon.com (homepage and investor relations section)
  4. [verwijderd] 27 maart 2007 15:47

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Na 10 minuten en 1.000.000 aandelen nu in de plus: +10 cents (4.63).

    Na het lezen van de briefings blijken er normale, goed beantwoordbare antwoorden gegeven te kunnen worden.
    50% is geen probleem: de veiligheid. Hier zal unaniem ja op gezegd worden.
    De andere 50% is lastiger. Provenge haalde de uitgangshypothes niet, maar gaf wel levensverlenging (+ 4 maanden in een onderzoek).
    Als Taxotere al toestemming krijgt met 2.8 maanden en veel bijwerkingen, dan is er meer dan 75% kans, dat Provenge goedgekeurd wordt.

    Het feit, dat de koers nu al weer op ++ 21 cents staat, geeft dat wel een beetje aan.

    Psycho
  5. svenhedin 27 maart 2007 15:49

    • svenhedin

      Lid sinds: 20 aug 2003

      Laatste bezoek: 16 jul 2024

    • Aanbevelingen

      Ontvangen: 81

      Gegeven: 331

    •    Aantal posts: 2.948

    quote:

    psycho-pharma schreef:

    Na 10 minuten en 1.000.000 aandelen nu in de plus: +10 cents (4.63).

    Na het lezen van de briefings blijken er normale, goed beantwoordbare antwoorden gegeven te unnen worden.
    %0% is geen probleem: de veiligheid. Hier zal unaniem ja op gezegd worden.
    De andere 50% is lastiger. Provenge haalde de uitgangshypothes niet, maar gaf wel levensverlenging (+ 4 maanden in een onderzoek).
    Als Taxotere al toestemming krijgt met 2.8 maanden en veel bijwerkingen, dan is er meer dan 75% kans, dat Provenge goedgekeurd wordt.

    Het feit, dat de koers nu al weer op ++ 21 cents staat, geeft dat wel een beetje aan.

    Psycho
    Bedankt voor je snelle beoordeling en melding hiervan. Aanbevolen.
  7. [verwijderd] 27 maart 2007 16:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Psycho, dankjewel voor je uitleg.
    Het is wel zo, dat de markt lijkt te twijfelen.
    Aanvankelijk iets omlaag, dan stabiel, nu wat omhoog, maar toch blijkt onzekerheid troef, begrijp ik uit de marktreactie.
  8. [verwijderd] 27 maart 2007 16:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    tonpa schreef:

    Psycho, dankjewel voor je uitleg.
    Het is wel zo, dat de markt lijkt te twijfelen.
    Aanvankelijk iets omlaag, dan stabiel, nu wat omhoog, maar toch blijkt onzekerheid troef, begrijp ik uit de marktreactie.
    er zijn ook gewoon kwesties
    biostatistische vraagtekens, maar dat was bekend

    milde bijwerkingen en dodelijke afloop en geen goed alternatief nog zijn de positieve punten
  9. [verwijderd] 27 maart 2007 16:20

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    ++ 30 cents

    WASHINGTON (Dow Jones)--The Food and Drug Administration Tuesday questioned the effectiveness of a proposed prostate cancer treatment from Dendreon Corp. (DNDN).

    The agency said two studies of the proposed drug, Provenge, failed to meet both primary and secondary endpoints in documents posted to its Web site. The drug faces a review on Thursday by an outside panel of medical experts who are being asked to make recommendations about whether the agency should approve Provenge.

    However, the FDA also said, "It appears that the two studies provide some evidence in support of using Provenge for the treatment of men with... prostate cancer." One study showed patients lived about four months longer on Provenge.

    Dendreon is asking the FDA to approve Provenge to treat men with advanced prostate cancer. If approved, Provenge would be a first-of-a-kind treatment for cancer because the drug is designed to stimulate a person's immune system to fight the cancer.

    -By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; Jennifer.Corbett@dowjones.com

    Psycho
    some evidence in support of using Provenge for the treatment of men with prostate cancer." One study showed patients lived about four months longer on Provenge..................
  13. [verwijderd] 28 maart 2007 14:53

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Van IV, by:prophet_of_profits

    March 28, 2007
    Dendreon's Last Day (Ahead of the FDA)
    Dendreon (DNDN-NASDAQ) has only 1 trading day left before its FDA panel meeting over the potential backing of its Provenge tomorrow. The FDA issued some critical postings last night ahead of its review that bring into question the real effectiveness of Provenge. The key difference in reality is going to be the accuracy of Dendreon's tests and the real measurement of time that this adds to life. Provenge is not a cure for prostate cancer, but some studies from the company have shown this to extend life for late stage prostate cancer patients.
    As expected, the FDA has given the proverbial curveball. It noted that Dendreon failed to meet certain effectiveness targets, but noted that two studies taken together do show some evidence that would support use of the vaccine. I have seen some very split reads on this: there are some mega-bulls and some mega-shorts in the name. As of March, its short interest grew to 26.4 million shares from a reading of 20.3 million shares in February; so now this represents 32% of the float. Combine that with all of the open interest in stock options between April and May and you can just expect one truly wild stock ride after the panel decision is released Thursday.
    If the panel backs this, then there is going to be a core following that gets behind Dendreon similar to that of Imclone, albeit on perhaps a smaller scale because of the market capitalization and analyst coverage differentials. If it fails to win panel backing, we showed how the street would try to evaluate it. The third possible scenario is that the FDA simply delays a decision by asking for more data, therefore keeping its hopes alive with what would amount to delays.
    The company also has its securities shelf filing active, so if it gets the "request for more data" or even an approval then it could be presumed that they will raise cash. Expect shares to be halted all of Thursday for the FDA panel review.
    The options were quite active with the APR07 $5.00 CALLS trading 41,923 contracts (close of $1.12) and the APR07 $5.00 PUTS trading 24,737 contracts $1.72 close). With DNDN closing at $4.62, this one is still pricing in a hell of a move. Tuesday's volume was again strong, with more than 10 million shares changing hands.
    Jon C. Ogg
    March 28, 2007
    Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

    www.247wallst.com/2007/03/dendreons_l...

    www1.investorvillage.com/smbd.asp?mb=...
  16. [verwijderd] 28 maart 2007 19:28

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=tonpa]
    Gaat lekker los. Nieuws kan ik niet vinden.
    [/quote]

    morgen beslissing!

    plus net item op CBS ofzo met david miller
    Dat wist ik natuurlijk, maar om nou opeens zo tekeer te gaan!
  17. [verwijderd] 28 maart 2007 19:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Today's In Play
    13:26 DNDN Dendreon: Provenge follow-up (5.07 +0.45) -Update-

    As mentioned at 13:18, CNBC noted that tomorrow, March 28. DNDN will face an FDA panel that will vote on its clinical trial for Provenge. It was noted that the FDA usually follows the advice of this panel. Currently, this clinical trial is a ten patient study. CNBC noted that DNDN is a heavily short stock with people betting against this trial. They note a positive ruling could have major implications for the sector.
  19. [verwijderd] 28 maart 2007 19:38

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    Today's In Play
    13:26 DNDN Dendreon: Provenge follow-up (5.07 +0.45) -Update-

    As mentioned at 13:18, CNBC noted that tomorrow, March 28. DNDN will face an FDA panel that will vote on its clinical trial for Provenge. It was noted that the FDA usually follows the advice of this panel. Currently, this clinical trial is a ten patient study. CNBC noted that DNDN is a heavily short stock with people betting against this trial. They note a positive ruling could have major implications for the sector.
    Very Positive Piece By Huckmsn - RECAP

    Huckman had a 71 Year old man on whose prostate cancer came back after being treated with chemo/radiation and refused to go through it again. His doctor put him in a provenge trial and 15 months later he still feels great.

    Heavily Shorted stock.

    Biotech Monthly Research Analyst David Miller was on and he believes it will be approved.

    Huckman mentioned the V factor could weigh in as in "Von Eschenbach". Von E has and his father had prostate cancer.

1.743 Posts
Pagina: «« 1 ... 29 30 31 32 33 ... 88 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.496
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.659
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.654
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.841
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.336
Air France - KLM 1.025 35.043
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.040
Alfen 16 24.849
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.224
AMG 971 133.345
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 14.999
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.709
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.103
ASML 1.766 107.287
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392